Cargando…

Pergolide Mesilate May Improve Fatigue in Patients with Parkinson’s Disease

Objectives: Fatigue is a complaint frequently encountered among patients with Parkinson’s disease (PD). Considering the possible relationship between fatigue and dopaminergic dysfuncion, we investigated the effect of pergolide mesilate (a D2 and D1 dopamine receptor agonist) and bromocriptine (a D2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abe, Kazuo, Takanashi, Mayako, Yanagihara, Takehiko, Sakoda, Sabro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2002
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507127/ https://www.ncbi.nlm.nih.gov/pubmed/12446951 http://dx.doi.org/10.1155/2002/473140

Ejemplares similares

Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease
por: Apostolakis, Efstratios E, et al.
Publicado: (2009)

Topical Pergolide Enhance Corneal Nerve Regrowth Following Induced Corneal Abrasion
por: Zhang, Xiaohui, et al.
Publicado: (2020)

Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling
por: Oury, Cécile, et al.
Publicado: (2020)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction
por: Gehlen, Heidrun, et al.
Publicado: (2021)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction
por: Fortin, Jessica S., et al.
Publicado: (2020)

Acute eosinophilic pneumonia caused by camostat mesilate: The first case report
por: Ota, Shinichiro, et al.
Publicado: (2016)

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
por: Kim, Joo Seong, et al.
Publicado: (2022)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia
por: Gordois, A, et al.
Publicado: (2003)

Randomized trial of betahistine mesilate tablets as augmentation for oxcarbazepine and carbamazepine in treating vestibular paroxysmia
por: Xue, Hui, et al.
Publicado: (2018)

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
por: Han, Sung Joon, et al.
Publicado: (2018)

Decision-Making Impairments in Patients with Parkinson’s Disease
por: Brand, Matthias, et al.
Publicado: (2004)

Nafamostat Mesilate: Can It Be Used as a Conduit Preserving Agent in Coronary Artery Bypass Surgery?
por: Yoon, Yoo Sang, et al.
Publicado: (2013)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway
por: Choi, Sujeong, et al.
Publicado: (2016)

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
por: Sugano, Hiroshi, et al.
Publicado: (2018)

Apolipoprotein E Genotypes in Mexican Patients with Parkinson's Disease
por: Gallegos-Arreola, M.P., et al.
Publicado: (2009)

DJ-1 Variants in Indian Parkinson’s Disease Patients
por: Sadhukhan, Tamal, et al.
Publicado: (2012)

Dual Task Performance in Parkinson’s Disease
por: Foley, Jennifer A., et al.
Publicado: (2013)

Parkinson’s Disease Protects Against Smoking?
por: Allam, Mohamed Farouk, et al.
Publicado: (2004)

Auditory Evoked P300 Potential in Patients With Parkinson’s Disease
por: Rajendran, Dhivya, et al.
Publicado: (2023)

The Pathophysiology of Impulse control Disorders in Parkinson Disease
por: Balarajah, Sharmili, et al.
Publicado: (2013)

Fatigue in Brazilian patients with Parkinson’s disease
por: Nassif, Daniel Venturino, et al.
Publicado: (2022)

The dimensionality of fatigue in Parkinson’s disease
por: Chong, Raymond, et al.
Publicado: (2018)

The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations
por: Chen, Xuanmao, et al.
Publicado: (2010)

Inhibition of intimal hyperplasia by local perivascular application of rapamycin and imatinib mesilate after carotid balloon injury
por: Park, Daedo, et al.
Publicado: (2013)

Enteral administration of the protease inhibitor gabexate mesilate preserves vascular function in experimental trauma/hemorrhagic shock
por: J. D. Moreira, Nathalia, et al.
Publicado: (2023)

Camptocormia in Parkinson's Disease
por: Abe, Kazuo, et al.
Publicado: (2010)

The Role of Dopamine Replacement on the Behavioural Phenotype of Parkinson’s Disease
por: Alobaidi, Hajar, et al.
Publicado: (2013)

Validation of the Parkinson Fatigue Scale in Chinese Parkinson's disease patients
por: Fu, Rao, et al.
Publicado: (2017)

A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
por: Kinoshita, Taku, et al.
Publicado: (2022)

Progressive Micrographia Shown in Horizontal, but not Vertical, Writing in Parkinson’s Disease
por: Ma, Hui-Ing, et al.
Publicado: (2013)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4l5g9qbmu2g8lvqssu4o5gt6f7